Tirzepatide Patent Expiration
Tirzepatide is Used for long-term weight management in adults who are overweight or obese with at least one weight-related comorbid condition. It was first introduced by Eli Lilly And Co
Tirzepatide Patents
Given below is the list of patents protecting Tirzepatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mounjaro | US11357820 | GIP/GLP1 agonist compositions | Jun 14, 2039 | Eli Lilly And Co |
| Mounjaro (autoinjector) | US11357820 | GIP/GLP1 agonist compositions | Jun 14, 2039 | Eli Lilly And Co |
| Zepbound | US11357820 | GIP/GLP1 agonist compositions | Jun 14, 2039 | Eli Lilly And Co |
| Zepbound | US11918623 | GIP/GLP1 agonist compositions | Jun 14, 2039 | Eli Lilly And Co |
| Zepbound (autoinjector) | US11357820 | GIP/GLP1 agonist compositions | Jun 14, 2039 | Eli Lilly And Co |
| Zepbound (autoinjector) | US11918623 | GIP/GLP1 agonist compositions | Jun 14, 2039 | Eli Lilly And Co |
| Mounjaro | US9474780 | GIP and GLP-1 co-agonist compounds | Jan 05, 2036 | Eli Lilly And Co |
| Mounjaro (autoinjector) | US9474780 | GIP and GLP-1 co-agonist compounds | Jan 05, 2036 | Eli Lilly And Co |
| Zepbound | US9474780 | GIP and GLP-1 co-agonist compounds | Jan 05, 2036 | Eli Lilly And Co |
| Zepbound (autoinjector) | US9474780 | GIP and GLP-1 co-agonist compounds | Jan 05, 2036 | Eli Lilly And Co |
| Mounjaro (autoinjector) | US9402957 | Automatic injection device with delay mechanism including dual functioning biasing member | Jun 29, 2031 | Eli Lilly And Co |
| Zepbound (autoinjector) | US9402957 | Automatic injection device with delay mechanism including dual functioning biasing member | Jun 29, 2031 | Eli Lilly And Co |
| Mounjaro (autoinjector) | US8734394 | Automatic injection device with delay mechanism including dual functioning biasing member | Feb 24, 2031 | Eli Lilly And Co |
| Zepbound (autoinjector) | US8734394 | Automatic injection device with delay mechanism including dual functioning biasing member | Feb 24, 2031 | Eli Lilly And Co |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tirzepatide's patents.
Latest Legal Activities on Tirzepatide's Patents
Given below is the list recent legal activities going on the following patents of Tirzepatide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 05 Mar, 2024 | US11918623 |
| Email Notification Critical | 05 Mar, 2024 | US11918623 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918623 |
| Recordation of Patent Grant Mailed Critical | 05 Mar, 2024 | US11918623 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918623 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918623 |
| Email Notification Critical | 15 Feb, 2024 | US11918623 |
| Issue Notification Mailed Critical | 14 Feb, 2024 | US11918623 |
| Dispatch to FDC | 31 Jan, 2024 | US11918623 |
| Application Is Considered Ready for Issue Critical | 31 Jan, 2024 | US11918623 |
Tirzepatide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tirzepatide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Tirzepatide has 8 clinical trials that have been verified in 2024. Out of these 8, 1 trial is in PHASE4.